AIM: To study the development of children with selectively treated cytomegalovirus infection.
PATIENTS AND METHODS: We studied prospectively a risk group of 12 children with cytomegalovirus infection. These children were diagnosed by serological screening in the first three months after birth and are defined as congenital and perinatal infections. Thirteen infants with no serological evidence of previous or present cytomegalovirus infection at 4 - 12 months of age were used as controls. Ganciclovir in a dose of 10-15 mg/kg/day for at least 2 weeks followed by 5-7.5 mg/kg/day administered intravenously for at least 2 weeks more was given to 4 children from the risk group with PCR confirmed cytomegalovirus infection: to one with suspected congenital infection that presented with encephalitis, to two children with abnormal auditory evoked potentials (AEPs) and other non-neurological symptoms of a suspected congenital infection, and to one child with proven congenital infection with systemic manifestations. There was no infant with cytomegalic inclusion disease in the study. All other children in the risk group that had clinically manifested infection received isoprinosine in a dose of 50 mg/kg for one month.
RESULTS: Psychomotor development delay at age three was found in two children from the risk group and in one child in the control group. There was no difference between the two groups regarding the frequency of paroxysmal events, sensory deficiency or frequent illnesses.
CONCLUSIONS: The prognosis in cases of cytomegalovirus infection diagnosed at three years of age and treated selectively can be similar to that in infection free 3-year-old children (if there are no cases of CMV inclusion disease).
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Stagno S. Cytomegalovirus. In: Kliegman RM Behrman RE Jenson HB Stanton BF eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia: Saunders Elsevier; 2007 (electronic edition). Chapter 252.
2. Schleiss MR. Cytomegalovirus Infection. In: Emedicine. Available at: http://emedicine.medscape.com/article/963090-print. Updated on Apr 19 2010. Accessed on Aug 17 2010.
3. Wong D. Cytomegalovirus. In: Wong’s virology. Available at: http://virology-online.com/viruses/CMV.htm. Accessed on Jan 12 2010.
4. Ivanov I Popov N Moshe R et al. Results of cytomegalovirus infection screening of hospitalized children up to 1 year old. Nauka i Mladost [Compendium of award-winning scientific communications from the 2005 and 2006 competitions]. Plovdiv Medical University Plovdiv; 2006:41-54 (Bulgarian).
5. Gandhi RS Fernandez-Alvarez JR Rabe H. Management of congenital cytomegalovirus infection: an evidence-based approach. Acta Paed 2010;99(4): 509-15.
6. Trincado DE Rawlinson WD. Congenital and perinatal infections with cytomegalovirus. J Paediatr Child Health 2001;37(2):187-92.
7. Kimberlin DW Lin CY Sanchez PJ et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized controlled trial. J Pediatr 2003;143(1):16-25.
8. Ivanov I Stefanov R. Cytomegalovirus infection at age one (ІІ): diagnosis treatment prophylaxis. Pediatria 2003;43(1):15-19 (Bulgarian).
9. Smets K De Coen K Dhooge I et al. Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy. Eur J Pediatr 2006;165(12): 885-90.
10. Lackner A Acham A Alborno T et al. Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up. J Laryngol Otol 2009;123(4):391-6.
11. Avila-Agiiero ML Paris MM Alfaro W et al. Ganciclovir therapy in cytomegalovirus (CMV) infection in immunocompetent pediatric patients. Int J Infect Dis 20037(4):278-81.
12. Kim CS. Congenital and perinatal cytomegalovirus infection. Korean J Pediatrics 2010;53(1):14-20.